started · updated
Serplulimab shows positive results in small cell lung cancer study
Henlius Biotech Inc. and Accord Healthcare UK have announced positive results from the Astride study, a randomized open-label descriptive study conducted in the United States. The study evaluated the efficacy and safety of serplulimab, an anti-PD-1 monoclonal antibody, compared to the standard of care, atezolizumab, in adult patients with extensive-stage small cell lung cancer (Es-Sclc).
The results, presented at the ESMO congress in Madrid, showed a median overall survival of 12.39 months for patients treated with serplulimab, compared to 10.15 months for those receiving atezolizumab, representing a numerical difference of 2.24 months. The Astride study was designed to provide the FDA with additional data on serplulimab in a population more representative of Western clinical practice to support the phase 3 Astrum-005 clinical trial results.
Entities
Accord Healthcare UK · ESMO · FDA · Henlius Biotech Inc. · atezolizumab · serplulimab
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 2 SOURCES] Median overall survival was 10.15 months with atezolizumab. www.ilfattonisseno.it · quotidianodibari.it
- [● 3 SOURCES] Serplulimab is an anti-PD-1 monoclonal antibody. www.ilfattonisseno.it · www.notizie.it · quotidianodibari.it
- [● 2 SOURCES] The Astride study was designed to support the evaluation of the phase 3 Astrum-005 clinical trial. www.ilfattonisseno.it · quotidianodibari.it
- [● 3 SOURCES] The Astride study was conducted in the United States on adults with extensive-stage small cell lung cancer. www.ilfattonisseno.it · www.notizie.it · quotidianodibari.it
- [● 3 SOURCES] The study was conducted in response to an FDA request for additional data on serplulimab. www.ilfattonisseno.it · www.notizie.it · quotidianodibari.it
- [● 3 SOURCES] Henlius Biotech Inc. and Accord Healthcare UK announced results from the Astride study. www.ilfattonisseno.it · www.notizie.it · quotidianodibari.it
- [● 2 SOURCES] Median overall survival was 12.39 months with serplulimab. www.ilfattonisseno.it · quotidianodibari.it
- [● 3 SOURCES] The study was designed to evaluate serplulimab against the standard of care, atezolizumab. www.ilfattonisseno.it · www.notizie.it · quotidianodibari.it